184V and of the 70R mutations was comparable between these two groups. The 74V substitution was never observed and the 75T mutation was detected in only two subjects non-responder to a stavudine including regimen. Reduced susceptibility to didanosine or stavudine was infrequent. Reduced susceptibility to zidovudine was observed in 25% of individuals failing a zidovudine including regimen, whereas reduced susceptibility to lamivudine was detected in all subjects failing a lamivudine including regimen. In the prospective analysis, patients with undetectable viral load at enrollment had a lower incidence of failure rate over one year compared to those with detectable HIV-RNA at entry (P < 0.0001). A detectable viral load at enrollment was the only independent variable that predicted clinical failure over one year (P < 0.0001).
Development of resistance to antiretroviral drugs is an independent risk factor for a poor virologic response (1) . The backbone of antiretroviral therapy is still represented by nucleoside reverse transcriptase inhibitors (NRTIs). However, many issues concerning resistance to this class of drugs are yet to be fully addressed.
HIV -infected individuals with high level resistance to zidovudine have a higher likelihood to progress to AIDS or to die (2) (3) (4) . Furthermore, the presence of the 215YIF mutation or of phenotypic resistance to zidovudine has been associated with a more rapid decline in CD4+ T-lymphocytes (5) and with a worse virological response (6, 7) , in patients receiving zidovudine. Nevertheless, a clearcut correlation between zidovudine resistance and treatment failure was not demonstrated in a subgroup of patients enrolled in the Delta trial (8) . Mutations associated with resistance to zidovudine could be selected also during treatment with either didanosine (9) , orstavudine (10, 11) , or both (12, 13) . However, a relevant decrease in didanosine or stavudine susceptibility was not observed in the presence of these substitutions (13) . High level resistance to lamivudine occurs quickly in individuals treated with this drug and without a complete suppression of viral replication, and is associated with the appearance of the 184V mutation (14) . However, patients with lamivudine resistance may have persistently low levels of viremia (14) (15) (16) (17) . Furthermore, variants resistant to lamivudine may have a reduced susceptibility also to zalcitabine, didanosine and abacavir (18, 19) . By contrast, lamivudine resistant isolates may have an enhanced susceptibility to zidovudine, and lamivudine can delay resistance to zidovudine (16, 20, 21) . Resistance to didanosine or stavudine is a rare finding and the correlation with specific mutations is uncertain (22) . In early studies, resistance to didanosine was usually associated with the 74V mutation (23, 24) , but it is noteworthy that the 74V mutation has not been reported among patients failing didanosine plus stavudine (12, 13) .Moreover, in larger studies, the 74V substitution was poorly related to resistance to didanosine (22) . Resistance to stavudine is even a more complex issue: patients treated with stavudine monotherapy rarely develop the 75T mutation (25) . However, Lin and colI. (10) found that variants carrying this mutation had IC50 levels corresponding to a wild-type phenotype, whereas two further patients in this study harbored virus strains showing an elevated stavudine IC50, but not bearing the 75T mutation. Furthermore, a correlation between the 75T mutation and phenotypic resistance to stavudine has not been demonstrated in patients treated with didanosine plus stavudine (13) and in larger cohorts (22) . Finally, it must be outlined that during combination therapies multidrug-resistant isolates or previously unreported mutations can arise. For instance, a virus with five previously unidentified mutations (62V + 751 + 77L + 116Y + 151M) that was resistant to zidovudine, didanosine, zalcitabine and stavudine, and partially to lamivudine, has been isolated from patients receiving zidovudine plus didanosine (26) or didanosine plus stavudine (12, 13) .
At the moment of the beginning of this study, in Italy many patients were still receiving a dual nucleoside therapy. At least three reasons accounted for the maintenance of this sub-optimal regimen: the patient initiated antiretroviral treatment before protease inhibitors and non-NRTIs were widely available and had still a good control of viral replication; the patient had liver function abnormalities that advised not to add a third drug; the patient did not agree to be treated with a more complex combination of drugs. We hypothesized that the prospective study of a population of patients receiving only two nucleoside analogues could provide a unique insight in viral resistance to this class of drugs.
The Study on Mutations and AntiRetroviral Treatment (SMART) was then designed with the following two objectives: to assess the prevalence of mutations associated to resistance in responder and non responder patients to dual nucleoside analogues therapy, and to evaluate the incidence of failure in patients responder to two NRTIs, with or without reverse transcriptase (RT) pol gene mutations.
MATERIALS AND METHODS

Study design
SMART involved 20 centers throughout Italy. Genotypic resistance to nucleoside analogues was evaluated between May 1997 and May 1999 in 527 HIV-I-infected subjects, responder or non-responder to a therapy with 2 NRTIs. In a subgroup of nonresponders, phenotypic resistance was also investigated.
Patients were evaluated in a cross-sectional and in a prospective study. In the cross-sectional study we enrolled individuals responder or non-responder to a therapy with 2 NRTIs (zidovudine or stavudine plus didanosine or lamivudine). Responders were defined by the presence, at enrollment, of an undetectable plasma viral load (pVL) or ofa reduction of HIV-RNA levels of greater than 210g10,compared to the beginning of therapy, after at least 6 months of stable treatment. In these patients genotyping was performed at enrollment ifHIV-RNA was detectable; otherwise it was performed at the time of treatment failure. Non-responders were patients with virological failure to an identical antiretroviral regimen. Virological failure was defined by the detection of a greater than 0.5 10gIO increase in pVL, compared to the virological nadir reached, after at least 6 months of stable therapy. In order to evaluate the correlation between the presence of RT mutations and clinical failure, responder patients were followed prospectively for one year. Clinical failure was defined as virological failure or loss of CD4+ T-Iymphocytes of greater than 30% or occurrence of new opportunistic conditions or relapse of opportunistic conditions.
Genotyping
In two centers mutations have been evaluated by direct sequencing of the RT pol gene: RNA was reverse transcribed and amplified in a nested PCR-protocol, as previously described (27) . Sequencing reactions were performed by the Big-dye Terminators (Perkin-Elmer, Norwalk, Connecticut, USA) following the protocols suggested by the manufacturer, and analyzed by a 377 ABI-Perkin-Elmer Automatic Sequencer. Sequence analysis and alignments were performed by means of Software Navigator (ABI-PE). This procedure did not allow the detection of codon 333 mutations. In the remaining centers RT mutations have been evaluated by LiPA (Innogenetics, Ghent, Belgium).
Phenotyping Viral phenotype was assessed by Antivirogram (performed by Vireo Laboratories, Mechelen, Belgium, on 1 mL of plasma stored frozen at -80°C) in a subgroup of non-responder patients. USA), or by b-DNA (Chiron Diagnostics, Emeryville, California, USA). Each center was allowed to choose one assay, but could not change it during the study period.
Statistical analysis
The prevalence of mutations in different groups of patients was assessed by Chi-square test. The number of zidovudine-related mutations among different groups was compared by the Wilcoxon rank-sum test. To assess the association between baseline viral load or the presence of mutations and the occurrence of clinical failure we used Kaplan-Meier survival analysis. Cox proportional-hazard regression model was employed to identify variables independently associated with failure probability. Variables taken into account in the multivariate analysis were the presence or the absence of mutations, each RT substitution, CD4+ cell counts, and HIV-RNA at baseline. All analyses were performed by SAS statistical package (SAS Institute Inc., Cary, North Carolina, USA).
Definition of reduced susceptibility
As stated by Vireo to interpret the Antivirogram(TM) assay, reduced susceptibility was defined by a greater than 4-fold, 4.5-fold, 3.5-fold and 3-fold increase in the IC50 of zidovudine, lamivudine, didanosine and stavudine respectively.
Viral quantification
HIV -RNA was assessed in each center either by NASBA (Organon, Teknika, Boxtell, Netherlands), or by Amplicor (Roche Biomedical Laboratories, Raritan, New Jersey and Research Triangle Park, North Carolina,
RESULTS
Cross-sectional study
Three hundred forty-two subjects were enrolled in the responder group. Eighty-five, 114, 30 and 113 were receiving zidovudine plus didanosine, zidovudine plus lamivudine, stavudine plus didanosine and stavudine plus lamivudine respectively. At enrollment, mean (SD) CD4+ Tlymphocytes were 567 (243)/J1.L, and median (range) pVL was 250 (20-16,000) HIV-RNA copies/mL. Table I and II. The 215YIFand the 70R mutations were detected in 22.3% and in 19.5% of patients treated with zidovudine, respectively. Further, zidovudine-related substitutions were observed in 9 out of 19 (47.4%) zidovudine-naive subjects receiving stavudine plus didanosine. The l84V substitution was detected in the vast majority (79.5%) of individuals on therapy with a lamivudine including regimen. The 74V mutation was never observed, whereas variants bearing the 75T mutation were detected only in two subjects failing a stavudine including regimen. The prevalence of the 70R and of the 184V substitutions was similar among responder and non-responder patients (33.3% vs. 32 .7%, P = 0.9 and 53.7% vs. 55.3%, P = 0.8, respectively). Conversely, the prevalence of the 215Y/F mutation was significantly higher among non-responder, compared to responder patients (33.7% vs. 17%, P =0.0005). Also, a significant increase in the number of zidovudine related mutations was observed among non-responder compared to responder subjects (P = 0.0(2). The prevalence of the 215YIF mutation was significantly higher among individuals on therapy with zidovudine plus didanosine, compared to those receiving zidovudine plus lamivudine (46.2% vs. 15.9%, P < 0.0001). Reduced susceptibility to zidovudine was observed in six out of 10 (60%) patients failing zidovudine plus didanosine and in none out of 14 subjects failing zidovudine plus lamivudine, whereas reduced susceptibility to lamivudine was detected in all patients failing a lamivudine including regimen. By contrast, a reduced susceptibility stavudine was observed in one out of 10 patients failing zidovudine plus didanosine and in one out of three subjects failing stavudine plus didanosine, whereas a reduced susceptibility to didanosine was detected in one out of three individuals failing stavudine plus didanosine and in one out of 13 patients failing stavudine plus lamivudine (Table III) .
Prospective study
The 342 subjects that were responder to two NRTls at enrollment entered this section of the study. Patients with undetectable pVL at enrollment had a lower risk of clinical failure over one year, compared to those with detectable pVL at entry (P < 0.0001) (Figure 1 ). By contrast, the presence of RT mutations at enrollment was not associated with a significantly higher risk of clinical failure over one year (P = 0.4) ( Figure 2 ). However, a trend for a higher risk of clinical failure over one year in subjects harboring variants bearing the 215Y/F substitution, compared to those without this mutation, was observed (P =0.16) ( Figure 3 ). The only variable independently predicting clinical failure over one year was a detectable pVL at enrollment (hazard ratio 1.97, 95% confidence interval = 1.42 -2.74, P < 0.0001).
DISCUSSION
Our study evaluates the correlation between RT mutations and response to a dual NRTI therapy. Some biases might have influenced the results. We employed two methods to detect mutations; however, the prevalence of the 75T mutation was consistent with that observed in larger series (22) and it is unlikely that major differences exist between sequencing and LiPA with regard to the more frequent mutations. We also considered responder patients with detectable pVL. However, the detection of mutations in plasma of patients with undetectable pVL is very difficult and the assessment ofresistance from cellular DNA, beside being arduous as well, would not have allowed a comparison with data obtained from plasma. Thus, this was the only way to have a control group. Furthermore, a greater than 2 log 10 reduction in pVL unequivocally testifies an activity of a therapy.
Mutations associated with resistance to NRTIs have been found in most of the non-responder patients. However, our results confirm that virologic failure is not inevitably accompanied by resistance to all drugs in a treatment regimen (I). In particular, a reduced susceptibility to didanosine or stavudine, as well as the detection of the 74V or of the 75T mutation, was very infrequent. In our study, the proportion of zidovudine naive subjects treated with stavudine and didanosine and harboring variants bearing mutations classically related to zidovudine resistance was similar to that most recentl y reported (11) . In one case, a purified HIV-l RT from a zidovudine-resistant isolate demonstrated reduced inhibition by zidovudine triphosphate and by stavudine triphosphate compared to RT from a paired wild-type isolate, thus providing a biochemical evidence for cross-resistance between zidovudine and stavudine (28) . One possible explanation is that HIV -1 variants with zidovudine-related amino acid substitutions have a replicative advantage in the presence of stavudine and didanosine (12) . However, variants carrying zidovudine-related mutations did not show a relevant decrease in stavudine (or didanosine) susceptibility (13); moreover, we did not observe a reduced susceptibility to stavudine in isolates with these substitutions in most cases. Colonno et al. have recently found that phenotypic resistance to didanosine or stavudine is a very uncommon finding and usually unrelated to presence of the 75T or of the 74V mutation, respectively (22) . Thus, it seems unlikely that most failures to didanosine and stavudine are due to viral resistance. Prolonged treatment with zidovudine impairs the efficiency of phosphorylation of thymidine kinase (29) . A decline in the activity of zidovudine has been observed when the intracellular phosphorylation of the drug is reduced and stavudine is phosphorylated by the same mechanism as zidovudine; thus, a "cellular" resistance to zidovudine might lead to a reduced efficacy of stavudine (30) . It is possible that at least some of the failures to stavudine including regimens could be ascribed to "cellular" resistance developed as a consequence of previous zidovudine therapies (31) . Furthermore, it has been recently demonstrated that stavudine triphosphate is incorporated as efficiently as the natural substrate during both DNA-and RNA-dependent DNA polymerization, and this may provide an explanation for the observed lack of stavudine resistance mutations in HIV-1 RT isolates from AIDS patients receiving long-term stavudine therapy (32) .
The presence of the 215Y/F substitution, as well as the number of the zidovudine-related mutations, were significantly associated with virological failure, according to most reports demonstrating a correlation between zidovudine resistance and a worse clinical or virological outcome (2) (3) (4) (5) (6) (7) . Also, our results confirm that lami vudine can delay the appearance of zidovudine resistance and that, in the presence of a lami vudineresistant isolate, a reversion of phenotypic resistance to zidovudine can occur. Whether this implies that the replication of variants with the 215Y IF plus the 184V mutation can be suppressed by zidovudine in the absence of lamivudine is not defined and should be addressed by further studies. Our study failed to demonstrate an association between the 70R substitution and virological or clinical failure. This may be due to the fact that the 70R mutation usually leads to a less than 8-fold decrease in zidovudine susceptibility (33, 34 Virological failure to zidovudine including regimen can occur in a high proportion of patients without the 215YIF substitution or without reduced susceptibility to the drug. Given the fact that, in this study, the 70R mutation was not associated with a weaker virological response, it can be postulated that these failures are due to the low potency ofthe combinations or to poor compliance or to both.
Responder and non-responder subjects had a very high, but comparable, prevalence oflamivudine resistance. This is consistent with previous reports (14) (15) (16) (17) and may be due to both a decreased fitness and an enhanced RT fidelity of viral strains bearing the 184V mutation (35, 36) . However, it has been recently demonstrated that cytotoxic T-lymphocytes can specifically recognize lamivudine-resistant HIV -1 mutants, thus contributing to the control of drug-resistant virus (37, 38) . It has been suggested that in the presence of resistance to lamivudine the susceptibility to didanosine may be reduced (18, 30) . However, in our sample a reduced susceptibility to didanosine was demonstrated in only one out of 32 isolates carrying the 184V mutation.
Roughly half of the responder patients had undetectable plasma viral load (pVL) at enrollment, which is consistent with previous reports (39, 40) . In our cohort, patients who reached undetectable pVL with two nucleoside analogues had a lower failure rate over one year compared to those who have a reduction of> 2 log 10, but still detectable, pVL. On the converse, we did not found a correlation between RT mutations at baseline and clinical failure over one year. A trend toward a higher failure rate in the presence of the 2l5YIF substitution has been observed, but the effect ofthis mutant on clinical outcome might have been blunted by the relatively small sample size. However, in many patients with resistance to lamivudine or zidovudine viral replication may be impaired due to the presence of the 184V or of the 2l5Y or of the 2l9Q mutation (35, 41, 42) , although this may not be true for isolates bearing multiple zidovudine-related mutations (43) . One possible explanation for the poor correlation between baseline RT mutations and clinical failure over one year of follow-up might thus be the reduced fitness of variants. Furthermore, variants bearing RT mutations are better recognized by cytotoxic T-lymphocytes (38) . Therefore, a better immune control ofNRTI resistant HIV -1 variants might be hypothesized. Finally, it must be considered that many subjects failing a didanosine and/or a stavudine including regimen harbored viral strains without RT mutations.
In conclusion, the results of the SMART study confirm an association between genotypic resistance to zidovudine and virological failure. Furthermore, it shows a very high prevalence of lamivudine resistance in both responder and non-responder to a combination of two NRTIs, whereas a reduced susceptibility to didanosine and stavudine, also among patients non-responder to an identical antiretroviral regimen, is very infrequent. Finally, it suggests that resistance to NRTIs is not always associated with failure, as well as that the absence of resistance to this class of drugs does not necessarily guarantee their efficacy. Thus, resistance testing for RT inhibitors seems to suggest which drugs to avoid rather than which drugs to deliver. Moreover, though genotyping may be a useful tool in the management of patients failing an antiretroviral regimen (44, 45) , the result of the test should however never be a substitute for good clinical judgment.
